HUJI MGC Pharma DC1: Brain Disorders (Nanodelivery of cannabinoids)

Project 1: Nanodelivery of cannabinoids for treating epilepsy

Despite the impressive therapeutic advances of CBD in seizure disorders, one major drawback is its high first-pass metabolism and low oral bioavailability in humans. We aim to design a Nose-to-Brain Nano-Delivery system that will increase CBD brain exposure, reduce the number of drug administrations, increase protection from seizures, decrease side effects and thus improve the treatment of epilepsy and other CNS diseases.

Supervisors: Dr Tawfeeq Shekh-Ahmad (HUJI), Prof. Sara Eyal (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma) 

Project 2: Nanodelivery of cannabinoids for treating autism

This project will focus on targeting the cannabinoids system in autism as a therapeutic strategy. The overarching goal is to develop nano-pharmaceutical formulations for the optimal delivery of cannabinoids for treating autism spectrum disorder (ASD). In particular transmucosal and other delivery methods will be tested to identify the most optimal methods.

Supervisors: Dr Haitham Amal (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma) 

Project 3: Nanodelivery of cannabinoids for migraine

Migraine is a common neurological disorder, characterised by moderate to severe headache and nausea. While there is not currently a cure for migraine, there are treatments and lifestyle changes that can help patients manage their migraine and enjoy a normal life. Cannabinoids have been demonstrated to possess nausea and pain relief properties. This project aims to develop nanoformulation for delivery of cannabinoids to treat migraine. 

Supervisors: Prof. Avi Priel (HUJI), A/Prof. Nitin Mantri (RMIT), Prof. Leslie Yeo (RMIT) and Jonathan Grunfeld M.D. (MGC Pharma) 

Share on facebook
Share on twitter
Share on linkedin
Share on email

Reference

HUJI MGC Pharma DC1

Research Areas

Biomedical Sciences, Biotechnology and biological sciences, Nanotechnology, Pharmacy, Autism, Behavioural, Cannabinoids, Cell signalling , applied science

Research Host

Hebrew University of Jerusalem (HUJI)

PhD awarding institution/s

Hebrew University of Jerusalem (HUJI) - RMIT University

Location

Israel

Status

Closed Position

RMIT University

Other Positions

Supervisors

Associate Prof. Andrey Molotnikov (RMIT), Professor Dr.-Ing. Thomas Niendorf (UoK), Philipp Krooss (UoK) and Dr. Markus Weinmann (UoK)

PhD awarding institution/s

University of Kassel (UoK) and RMIT University

Location

Germany

Status

Open Position

Supervisors

Prof. Jenny Zhang (RMIT) and Prof. Jose Antonio Vilar-Fernandez (UDC) and José Luis González Leal (Navantia) and Prof. Amparo Alonso-Betanzos (UDC) and Prof. Vicente Díaz-Casas (UDC) and Prof. Marcos Miguez González (UDC)

PhD awarding institution/s

University of A Coruña (UDC) and RMIT University

Location

Spain

Status

Open Position

Supervisors

Prof. Anne-Laure Mention (RMIT) and Associate Prof. Carsten Nico Hjortso (UPCH) and Dr. Marie Smed (UPCH)

PhD awarding institution/s

University of Copenhagen (UCPH) and RMIT University

Location

Denmark

Status

Open Position

RMIT and many of the REDI partners are HSR4R certified
europe-1-1.svg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101034328.

Results reflect the author’s view only. The European Commission is not responsible for any use that may be made of the information it contains